Abstract
We review recent precision oncology literature pertaining to the implications of germline and somatic genetic information in cancer treatment. The goal of this work is to provide a practical resource for oncology practitioners and genetic providers and discuss practice considerations for those on the frontline of precision oncology. Understanding germline and somatic tumor alterations, patients can be matched to targeted therapy options attacking the specific genetic makeup of that tumor. This information informs treatment decisions about which therapies the cancer is likely to respond to and which treatment options should be avoided. Timely access to germline and somatic genetic testing is critical to ensure that patients have this information for treatment planning, both at diagnosis and through later lines of therapy. The hope of precision oncology is here although significant challenges remain for implementation for routine cancer care.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
